Many studies have shown that promoter hypermethylation leads to the loss of DAPK1 expression in numerous tumor types, including chronic lymphocytic leukemia (Bodoor et al., 2014), chronic myeloid leukemia (Qian et al., 2009), diffuse large B-cell lymphoma (Kristensen et al., 2014), and lung cancer (Feng et al., 2008). This evidence concerns the gene DAPK1 and neoplasm.